In 2023, Vetoquinol Celebrates Its 90th Anniversary
April 24 2023 - 11:45AM
Business Wire
The animal health company is firmly established in the
world's Top 10.
Regulatory News:
Vetoquinol (Paris:VETO):
A family-owned and independent company
Vetoquinol has managed to preserve its family ownership and
independence while pursuing a growth strategy aimed at focusing its
efforts and resources on high-potential markets.
In 2023, the company is the 8th largest animal health
pharmaceutical company in the world, with a presence in 24
countries and around 50 distributors worldwide.
A growing animal health market
The animal health market is a strong, steadily developing market
that continues to grow thanks to product innovations, digital
technology and faster, more accurate diagnostics.
This market is supported by the constant growing demand for
animal proteins (milk, eggs, meat) worldwide and pet care, a
segment that is benefiting from the changing purchasing power of
pet owners.
Key markets for Vetoquinol
Europe has historically been Vetoquinol's largest market, with
subsidiaries in all major European countries. America, and
particularly the United States, the world's largest animal health
market, represents a strong growth potential. Asia/Pacific is a
territory with a promising future; the diversity and dynamics of
local markets will enable Vetoquinol to continue to grow in this
region.
A global strategy to be close to its customers.
International development has been a priority for Vetoquinol for
over 90 years. Through its network of subsidiaries and
distributors, the company is close to its customers. This proximity
allows the company to build solutions with them and to meet their
needs, while differentiating itself on its markets to sustain its
business.
ABOUT VETOQUINOL
Vetoquinol is a leading global animal health company that
supplies drugs and non-medicinal products for the farm animals
(cattle and pigs) and pet (dogs and cats) markets. As an
independent pure player, Vetoquinol designs, develops and sells
veterinary drugs and non-medicinal products in Europe, the Americas
and the Asia Pacific region. Since its foundation in 1933,
Vetoquinol has pursued a strategy combining innovation with
geographical diversification. The Group’s hybrid growth is driven
by the reinforcement of its product portfolio coupled with
acquisitions in high potential growth markets. Vetoquinol employed
more than 2,500 people as of December 31st, 2022.
Vetoquinol has been listed on Euronext Paris since 2006 (symbol:
VETO).
The Vetoquinol share is eligible for the French PEA and PEA-PME
personal equity plans.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230424005015/en/
VETOQUINOL Group Communications Officer Resika
Narain-Menigot resika.narain-menigot@vetoquinol.com KEIMA
COMMUNICATION Press Relations Charles-Edouard Aubry
Tel.: +33 (0)6 09 09 48 32 charles-edouard.aubry@keima.fr
Investors Relations Emmanuel Dovergne Tel.: +33 (0)6
76 94 40 87 emmanuel.dovergne@keima.fr
Vetoquinol (EU:VETO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vetoquinol (EU:VETO)
Historical Stock Chart
From Jul 2023 to Jul 2024